Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Respondents were clear about who they think these medications are really for
Although the research is promising, there are many factors that could potentially impact depression among people with obesity who are taking these medications (weight loss, physical activity, less medical burden, nutritional status, hopefulness, sleep, etc). Semaglutide and tirzepatide were the two medications most strongly related to decreased risk of depression and anxiety
For example, its not known yet if microdosing can actually result in the same level of weight loss as standard doses
The GLP-1 market represents a significant business opportunity for digital health solutions that can support behavior change among individuals with obesity and diabetes
US$ 24.76
US$ 25.52
US$ 26.28
US$ 25.75
US$ 28.84
US$ 27.25
